**Mast cell activation test in the diagnosis of allergic disease and anaphylaxis**

Rajia Bahri, PhD,a Adnan Custovic, MD, PhD,b Peter Korosec, PhD,7 Marina Tsoumani, MD,d Martin Barron, PhD,a Jiakai Wu, PhD,a Rebekah Sayers, PhD,d Alf Weimann, MEng,8 Monica Ruiz-Garcia, MD, b Nandinee Patel, MD, b Abigail Robb, BSc,d Mohamed H. Shamji, PhD, f Sara Fontanella, PhD, b Mira Silar, BSc, c E. N. Clare Mills, PhD, d Angela Simpson, FRCP, PhD, d Paul J. Turner, FRACP, PhD, b* and Silvia Bulfone-Paus, MD, PhD* a Manchester and London, United Kingdom, Golnik, Slovenia, and Lübeck, Germany

**GRAPHICAL ABSTRACT**

From the Division of Musculoskeletal and Dermatological Sciences & Manchester Collaborative Centre for Inflammation Research (MCCIR), School of Biological Sciences, University of Manchester;7 the Section of Paediatrics, Department of Medicine, and the Section of Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London; the Laboratory for Clinical Immunology & Molecular Genetics, University Hospital for Respiratory and Allergic Diseases, Golnik; 4 the Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre; and the EUROIMMUN AG, Lübeck.

*These authors contributed equally to this work as joint senior authors.

Supported by the following grants: Medical Research Council (MRC) Confidence-in-Concepts award to the University of Manchester (sub-award to S.B.-P. and P.J.T., reference MC-PC-15038); an MRC Clinician Scientist award funded (reference MR/K010468/1; to P.J.T.); and National Institute for Health Research (NIHR) Clinical Research Facility and Manchester Allergy and Respiratory Thoracic Surgery (MARTS) Biobank at University Hospital of South Manchester NHS Foundation Trust, which is supported by the NIHR Manchester Biomedical Research Centre. The clinical challenges were funded through the NIHR Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; the European Union’s Seventh Framework Program for research, technological development, and demonstration under grant agreement no. 312147 (Integrated Approaches to Food Allergen and Allergy Risk Management [iFAAM]); and the Slovenian Research Agency (reference J3-6787). R.S. was supported by the UK Biotechnology and Biological Sciences Research Council through a cooperative award in science and engineering with Campden BRI. P.J.T. and A.C. are supported by the Imperial/NIHR Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR, or the Department of Health. Disclosure of potential conflict of interest: A. Custovic has received personal fees from Novartis, Regeneron/Sanoﬁ, ALK-Abelló, Bayer, Thermo Fisher, GlaxoSmithKline, and Boehringer Ingelheim. A. Weimann is employed by EUROIMMUN AG. M. H. Shamji has received grants from ALK-Abelló, Regeneron, Merck, ASIT Biotech, sa, and the Immune Tolerance Network and has received personal fees from ASIT Biotech, sa, ALK-Abelló, Allergopharma, and UCB. E. N. C. Mills has received a grant from the UK Biological and Biotechnological Sciences Research Council, DBV Technologies, Reacta Biotech, the Medical Research Council, the European Union, and the UK Food Standards Agency and has patents pending to Reacta Biotech Ltd (PCT/GB2016/051637 and PCT/GB2016/053829). A. Simpson has received grants from the Medical Research Council, the JP Moulton Charitable Foundation, and the National Institute for Health Research and has received personal fees from Thermo Fisher Scientific. P. J. Turner has received grants from the UK Medical Research Council, the National Institute for Health Research, and the European Commission FP7 scheme. S. Bulfone-Paus has received grants from the UK Medical Research Council, GlaxoSmithKline, and Novartis and has received personal fees from EUROIMMUN AG. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication September 19, 2017; revised December 9, 2017; accepted for publication January 16, 2018.

Available online March 5, 2018.

Corresponding author: Silvia Bulfone-Paus, MD, PhD, Division of Musculoskeletal and Dermatological Sciences & Manchester Collaborative Centre for Inflammation Research (MCCIR), School of Biological Sciences, FBMM, University of Manchester, Core Technology Facility, Room 2.18a, 46 Grafton St, Manchester M13 9PT, United Kingdom. E-mail: silvia.bulfone-paus@manchester.ac.uk. Or: Paul J. Turner, FRACP, PhD, Section of Paediatrics, Imperial College London, Norfolk Place, London W2 1PG, United Kingdom. E-mail: p.turner@imperial.ac.uk.

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections 0091-6749 © 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). https://doi.org/10.1016/j.jaci.2018.01.043
Background: Food allergy is an increasing public health issue and the most common cause of life-threatening anaphylactic reactions. Conventional allergy tests assess for the presence of allergen-specific IgE, significantly overestimating the rate of true clinical allergy and resulting in overdiagnosis and adverse effect on health-related quality of life.

Objective: To undertake initial validation and assessment of a novel diagnostic tool, we used the mast cell activation test (MAT).

Methods: Primary human blood-derived mast cells (MCs) were generated from peripheral blood precursors, sensitized with patients’ sera, and then incubated with allergen. MC degranulation was assessed by means of flow cytometry and mediator release. We compared the diagnostic performance of MATs with that of existing diagnostic tools to assess in a cohort of peanut-sensitized subjects undergoing double-blind, placebo-controlled challenge.

Results: Human blood-derived MCs sensitized with sera from patients with peanut, grass pollen, and Hymenoptera (wasp venom) allergy demonstrated allergen-specific and dose-dependent degranulation, as determined based on both expression of surface activation markers (CD63 and CD107a) and functional assays (prostaglandin D2 and ß-hexosaminidase release). In this cohort of peanut-sensitized subjects, the MAT was found to have superior discrimination performance compared with other testing modalities, including component-resolved diagnostics and basophil activation tests. Using functional principle component analysis, we identified 5 clusters or patterns of reactivity in the resulting dose-response curves, which at preliminary analysis corresponded to the reaction phenotypes seen at challenge.

Conclusion: The MAT is a robust tool that can confer superior diagnostic performance compared with existing allergy diagnostics and might be useful to explore differences in effector cell function between basophils and MCs during allergic reactions. (J Allergy Clin Immunol 2018;142:485-96.)

Key words: Anaphylaxis, basophil activation test, diagnosis, food allergy, mast cells, mast cell activation test, peanut allergy

IgE-mediated food allergy is an increasing public health issue with a prevalence of 6% in children and up to 2% in adults. It is the most common cause of anaphylaxis, a potentially life-threatening and rapidly progressing systemic allergic reaction that can lead to death caused by airway obstruction or cardiovascular collapse. The adverse effect of food allergy on the quality of life of children and their families is greater than that caused by diabetes and other chronic illnesses.

The gold standard test for diagnosis of food allergy is a double-blind, placebo-controlled food challenge (DBPCFC), in which increasing doses of food (or placebo) are administered under medical supervision. Open and unblinded oral food challenges are often performed as an alternative. However, oral food challenges are time-consuming, costly, and not without risk because of the potential for anaphylaxis or even death. In practice, IgE-mediated food allergy is usually diagnosed by using a surrogate marker, detection of allergen-specific IgE (sIgE) to the implicated food (referred to as sensitization) either in serum or through skin prick tests (SPTs). However, sensitization frequently fails to correlate with clinical reactivity: a positive allergy test result (either SPTs or IgE measurement to the whole allergen extract) is not diagnostic in isolation. A false-positive rate of greater 50% has been reported in population-based studies, and consequently, overdiagnosis of food allergy is common. This results in unnecessary dietary exclusions, social restrictions, and anxiety, which can further impair nutrition and quality of life.

To date, attempts to develop more accurate tests to diagnose food allergy have focused on 2 strategies: component-resolved diagnostics and the basophil activation test (BAT). Component-resolved diagnostics use purified native or recombinant allergens to detect sIgE to individual allergenic molecules rather than whole allergen extracts. Superior diagnostic accuracy has been demonstrated for peanut allergy, but data are limited and equivocal for other allergies.

In the BAT basophils from patients are incubated with allergen ex vivo, and surface expression of activation markers is measured by using flow cytometry. The BAT can improve diagnostic accuracy in patients with peanut allergy but is technically challenging and limited to a few specialist centers and lacks the accuracy and reproducibility of a food challenge. It has not been validated for other food allergens and needs to be evaluated further in terms of feasibility and cost-effectiveness outside specialist units.

Whether basophils are involved as effector cells in the pathophysiology of allergic reactions is unclear. Traditionally, mast cells (MCs) have been considered the main effector cells in patients with allergic reactions. After allergen exposure, these cells become activated through IgE cross-linking of FceRI expressed on the cell surface, resulting in release and de novo synthesis of inflammatory mediators. Despite sharing allergen-mediated activation mechanisms, MCs are transcriptionally distinct and independent from circulating granulocytes. Therefore we sought to develop an alternative approach to the diagnosis of allergic disease and anaphylaxis using primary human blood-derived mast cells (hMCs) generated from CD117+ peripheral blood precursors, which are passively sensitized with patients’ sera and then incubated in vitro with allergen; this is known as the mast cell activation test (MAT). In this report we describe development of the MAT, its potential application in patients with peanut and insect venom allergy, and initial validation.
as a diagnostic tool for peanut allergy compared with existing diagnostic tests.

METHODS
Study design
We developed a novel diagnostic tool, the MAT, in which primary hMCs generated from peripheral blood precursors from healthy donors were sensitized passively with patients’ sera and then incubated with allergen in vitro, and MC activation was assessed. All study participants provided written informed consent (UK NHS Human Research Authority reference 15/NW/040, 15/LO/0286, and 15/LO/0287 and Slovenian National Medical Ethics Committee reference 75/06/15).

Development of the MAT
Generation of hMCs from peripheral blood precursors. hMCs were generated, as previously described. Briefly, CD117+CD34+ cells were purified from buffy coat blood mononuclear cells by using a positive selection kit (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were cultured in serum-free StemSpan medium (STEMCELL Technologies, Vancouver, British Columbia, Canada) supplemented with 100 U/mL penicillin (Invitrogen, Carlsbad, Calif), 100 μg/mL streptomycin (Invitrogen), human IL-6 (50 ng/mL; PeproTech, Rocky Hill, NJ), human IL-3 (10 ng/mL; PeproTech), human stem cell factor (100 ng/mL; PeproTech), and 10 μg/mL human low-density lipoprotein (STEMCELL Technologies). After 30 days, the cells were transferred progressively to culture medium containing Iscove modified Dulbecco medium with GlutaMax-I, 50 mM b-mercaptoethanol, 0.5% BSA, 1% Insulin-Transferrin-Selenium (Life Technologies, Vancouver, British Columbia, Canada) supplemented with 100 U/mL penicillin (Invitrogen, Carlsbad, Calif), 100 μg/mL streptomycin, human IL-6 (50 ng/mL; PeproTech), and human stem cell factor (100 ng/mL). After 8 to 10 weeks of culture, the cells were tested for maturity and found to be greater than 90% CD117+ and FceRα+ cells.

We used immunocytochemistry to characterize hMCs generated from peripheral blood precursors (details are provided in the Methods section in this article’s Online Repository).

Passive sensitization of cultured primary hMCs. Cultured primary hMCs were sensitized passively with serum samples from subjects with a physician-confirmed peanut allergy recruited from the Allergy Centre at the University Hospital of South Manchester. All patients had a convincing history of immediate reaction on exposure to peanut and detectable serum specific IgE to whole peanut extract. Control serum was collected from patients with pollen allergy but no history of peanut allergy who were consuming peanuts and had negative IgE and/or SPT results to whole peanut extract.

To assess whether the MAT could be applied to nonfood allergens, we recruited 42 peanut-sensitized subjects who underwent DBPCFCs to peanut (details are provided in the Methods section in this article’s Online Repository). Patients who reacted on DBPCFC were considered to be allergic to peanut, whereas those who passed the challenge without experiencing dose-limiting symptoms were classified as sensitized but peanut tolerant.

Blood samples were collected immediately before challenge and transferred without delay for assessment of basophil activation or centrifuged, and sera were stored at –80°C until analysis.

Specific IgE to whole allergen extract, component-resolved diagnostics, and SPTs. Levels of total IgE, peanut-specific IgE, and IgE to the recombinant allergen components rAra h 1, 2, 3, 6, 8, and 9 were measured by using ImmunoCAP (Thermo Fisher Scientific, Uppsala, Sweden). SPTs were undertaken according to national guidelines by using lancets (ALK-Abelló, Hørsholm, Denmark) and commercial peanut extract (Stallergenes, Paris, France), with 1% histamine as a positive control.

BATS. BATS were performed, as described previously. In brief, heparinized whole blood (100 μL) from sensitized subjects was incubated with peanut allergen extract (ALK-Abelló) or anti-IgE (0.5 μg/mL) in a 37°C water bath for 15 minutes. Cells were immunostained with anti-human CD3, CD303, CD294 (chemoattractant receptor-homologous molecule expressed of Tp2 cells [CRTH2]), CD203c, CD63, and CD107a (all from BD Biosciences). Erythrocytes from whole blood were lysed with BD lysing solution (BD Biosciences) for 10 minutes at room temperature in the dark, samples were centrifuged (for 5 minutes at 200g), and supernatants were discarded. The resulting cell pellets were washed in 3 mL of PBS (without Ca2+ and Mg2+) and resuspended in 450 μL of ice-cold fixative solution (CellFix; BD Biosciences) before acquisition on the BD FACS Canto II flow cytometer. Nonactivated and activated basophils were identified as CD203c+CD294+ and CD203c+CD63+CD303+CRTH2+ cells, respectively. Additionally, activated cells were also identified as CD63+ and CD107a+CD3+CD303+CRTH2+ basophils. Analyses were performed with BD FACS Diva software (version 6.1.1; BD Biosciences).

Data and statistical analysis
Threshold sensitivity calculation.

To ensure quality control across batches of hMCs, in each run we included a reference positive control and anti-IgE. Each batch was generated from 3 to 9 pooled donors to reduce the risk of specific donor dependence.

Measurement of MC mediator secretion.
After incubation with allergen, 50-μL aliquots from cell cultures were taken and centrifuged to separate the supernatant and cell pellet. Cell pellets were lysed in 50 μL of media culture 1% Triton X-100. β-Hexosaminidase levels were measured in supernatants, as well as in cell pellets, by adding 100 μL of β-hexosaminidase substrate and 1 mmol/L p-nitrophenyl N-acetyl-beta-D-glucosamine (Sigma-Aldrich, St Louis, Mo) in 0.05 mol/L citrate buffer (pH 4.5) for 2 hours at 37°C in a 5% CO2 atmosphere. The reaction was stopped by adding 300 μL of 0.05 mol/L sodium carbonate buffer (pH 10). OD was measured at 405 nm. hMC degranulation was assessed as percentage release of total β-hexosaminidase. Prostaglandin D2 (PGD2) levels were measured in supernatants by using the ELISA kit from Cayman Chemical (Ann Arbor, Mich).

Validation, diagnostic performance, and comparison of the MAT with other diagnostic tests
Study participants, data sources, and other diagnostic tests for peanut allergy.
We recruited 42 peanut-sensitized subjects who underwent DBPCFCs to peanut (details are provided in the Methods section in this article’s Online Repository). Patients who reacted on DBPCFC were considered to be allergic to peanut, whereas those who passed the challenge without experiencing dose-limiting symptoms were classified as sensitized but peanut tolerant.

Blood samples were collected immediately before challenge and transferred without delay for assessment of basophil activation or centrifuged, and sera were stored at –80°C until analysis.

Specific IgE to whole allergen extract, component-resolved diagnostics, and SPTs. Levels of total IgE, peanut-specific IgE, and IgE to the recombinant allergen components rAra h 1, 2, 3, 6, 8, and 9 were measured by using ImmunoCAP (Thermo Fisher Scientific, Uppsala, Sweden). SPTs were undertaken according to national guidelines by using lancets (ALK-Abelló, Hørsholm, Denmark) and commercial peanut extract (Stallergenes, Paris, France), with 1% histamine as a positive control.

BATS. BATS were performed, as described previously. In brief, heparinized whole blood (100 μL) from sensitized subjects was incubated with peanut allergen extract (ALK-Abelló) or anti-IgE (0.5 μg/mL) in a 37°C water bath for 15 minutes. Cells were immunostained with anti-human CD3, CD303, CD294 (chemoattractant receptor-homologous molecule expressed of Tp2 cells [CRTH2]), CD203c, CD63, and CD107a (all from BD Biosciences). Erythrocytes from whole blood were lysed with BD lysing solution (BD Biosciences) for 10 minutes at room temperature in the dark, samples were centrifuged (for 5 minutes at 200g), and supernatants were discarded. The resulting cell pellets were washed in 3 mL of PBS (without Ca2+ and Mg2+) and resuspended in 450 μL of ice-cold fixative solution (CellFix; BD Biosciences) before acquisition on the BD FACS Canto II flow cytometer. Nonactivated and activated basophils were identified as CD203c+CD294+ and CD203c+CD63+CD303+CRTH2+ cells, respectively. Additionally, activated cells were also identified as CD63+ and CD107a+CD3+CD303+CRTH2+ basophils. Analyses were performed with BD FACS Diva software (version 6.1.1; BD Biosciences).
FIG 1. Peanut- and grass pollen–induced degranulation of hMCs sensitized with sera of patients with peanut and grass pollen allergy (sensitized to both peanut and pollen, n = 5; sensitized to peanut only, n = 1; sensitized to grass pollen but not peanut, n = 1). hMCs were sensitized overnight with sera from patients with peanut allergy, patients with grass pollen allergy, or both; washed; and either left untreated or exposed for 1 hour to anti-IgE (10 μg/mL) as a positive control (left), different concentrations of peanut extract (middle), or grass pollen extract (right). A and B, hMC degranulation was measured based on CD63 (Fig 1, A) and CD107a (Fig 1, B) surface staining and analyzed by using flow cytometry. C, β-Hexosaminidase levels were measured in cell pellets, as well as in supernatants. Percentage β-hexosaminidase release is shown. D, PGD2 levels were measured in supernatants. The assay was performed in duplicates or triplicates with pooled hMCs from at least 3 different healthy donors. Symbols indicate individual patients, and values indicate means ± SDs.
Functional data analysis. To identify distinct response profiles and their characteristics, we performed an exploratory analysis on the trajectories defined by the MAT measurements (details are provided in the Methods section in this article’s Online Repository). To uncover the dynamic of the latent allergic response process, we examined the discrete trajectories in a continuous way using functional data analysis (FDA). All of the FDAs were carried out in the MATLAB language using the toolbox for FDA. We then undertook FDA of the MATs. To mitigate the effect of the unequal intervals between allergen concentrations, we applied a logarithmic transformation of the form \( \log(x + c) \), with \( c = 0.001 \). For each patient, 6 measurements obtained through the MAT assay were converted into continuous curves by using B-spline basis functions. The resultant fitted curves formed the basis for subsequent analyses.

To identify the dominant modes of variation of the response patterns, we applied functional principal component (FPC) analysis to the fitted curves. We then used k-means clustering to estimate distinct response patterns. To determine the optimal number of clusters, we used several evaluation measures available through the R package NbClust. Further details of analyses can be found in the Methods section in this article’s Online Repository.

RESULTS

MAT development

Generation of hMCs from peripheral blood precursors. After 8 to 10 weeks of culture, hMCs derived from peripheral blood precursors had the phenotypic and functional properties of mature hMCs: they expressed CD117, surface IgE receptors that bound strongly to serum IgE (see Fig E1, A, in this article’s Online Repository at www.jacionline.org) and surface IgE receptors that bound strongly to serum IgE (see Fig E1, B). We confirmed the presence of tryptase and chymase using immunofluorescence (see Fig E1, C and D), with characteristic granularity patterns after staining with Giemsa and toluidine blue (see Fig E1, E and F).

Sensitized hMCs are highly sensitive to allergen-induced degranulation. We passively sensitized primary hMCs using sera from patients with peanut and pollen allergy. To assess their degranulation after stimulation with peanut and grass allergen extract, we measured surface expression of CD63 and CD107a (lysosomal-associated membrane protein 1) using flow cytometry and release of \( \beta \)-hexosaminidase (from intracellular granules) and PGD\(_2\) (secreted \( \text{de novo} \) after MC activation). In vitro incubation with allergen resulted in a dose-dependent increase in CD63 and CD107a membrane expression (Fig 1, A and B) and \( \beta \)-hexosaminidase release (Fig 1, C); all immunologic readouts correlated significantly (see Fig E2 in this article’s
Functional degranulation was further confirmed by the observation that allergen stimulation caused allergen-specific release of PGD<sub>2</sub> (Fig 1, D). Incubation with 10 μg/mL anti-IgE (as a positive control) resulted in a similar degree of degranulation (Fig 1). The hMC response was allergen specific, and there was no evidence of hMC activation or degranulation when we used sera from patients sensitized to allergens other than that used for stimulation.

Stimulation with anti-IgE resulted in greater surface expression of CD63 and CD107a and higher levels of β-hexosaminidase and PGD<sub>2</sub> release in hMCs compared with LAD2 cells (see Fig E3 in this article’s Online Repository at www.jacionline.org).

In summary, hMCs passively sensitized with sera from donors with peanut and/or pollen allergy were very sensitive to low doses of allergen. The sensitized hMCs demonstrated allergen-specific and dose-dependent degranulation by using both expression of surface activation markers and functional assays, indicating that hMCs are suitable as primary effector cells for screening studies. The correlation between immunologic parameters, we used CD63 expression as the readout in subsequent experiments.

Application of MATs in patients with peanut and wasp venom allergy. Peanut allergy. Primary hMCs were sensitized passively with sera from 14 patients with peanut allergy and 4 atopic control subjects without peanut allergy. All 14 patients with peanut allergy had a recent history of peanut-induced anaphylaxis (see Table E1 in this article’s Online Repository at www.jacionline.org). Incubation of passively sensitized hMCs with increasing concentrations of peanut extract resulted in a dose-dependent expression of CD63 in patients with peanut allergy but not in atopic control subjects (Fig 2, B). Anti-IgE induced a similar degree of CD63 expression (Fig 2, A). There was a significant correlation (R<sup>2</sup> = 0.89, P < .0001) between the level of hMC degranulation induced at 0.1 ng/mL peanut extract and the peanut-specific IgE titer (Fig 3). The CD-sens of the MAT<sup>25</sup> showed a weaker correlation with peanut-specific IgE levels, with the patient population appearing to separate into 2 groups (Fig 3, B).

Stimulation of hMCs (sensitized with sera from patients with peanut allergy) with the recombinant peanut proteins rAra h 1, rAra h 3, rAra h 2, and rAra h 6 also increased CD63 expression (Fig 2, C). The Bet v 1 homologue rAra h 8 (implicated in pollen-food allergy syndrome rather than primary allergy to peanut) did not induce substantial hMC degranulation in these patients (Fig 2, C). Fig 3, C, shows the correlation between IgE titers to allergen components and hMC degranulation.
**Wasp allergy.** hMCs were sensitized by using sera from 21 patients with a confirmed systemic reaction to wasp venom and 7 patients with previous systemic reaction to honeybee but not wasp venom (see Table E2 in this article’s Online Repository at www.jacionline.org). Incubation of passively sensitized hMCs with increasing concentrations of wasp venom extract resulted in a dose-dependent expression of CD63 in patients with wasp venom allergy but not those with honeybee venom allergy (see Fig E4 in this article’s Online Repository at www.jacionline.org).

**Validation, diagnostic performance, and comparison of MATs with other diagnostic tests.**

**Diagnostic cutoff values for MATs in patients with peanut allergy.** We performed MATs in a further cohort of 42 peanut-sensitized patients before they underwent DBPCFCs to peanut. Demographic and clinical characteristics of the study population are shown in Table I; 30 participants reacted to DBPCFCs and were classified as having peanut allergy, whereas 12 passed the challenge without experiencing dose-limiting symptoms and were categorized as sensitized but peanut tolerant.

Individual MAT dose-response curves are shown in Fig E5, A, in this article’s Online Repository at www.jacionline.org. By using ROC curve analysis, the MAT outcome measures with the best performance to discriminate patients with peanut allergy from peanut-tolerant patients were MAT response to crude peanut at 10 and 100 ng/mL concentrations and AUC for the dose-response curve (MAT-AUC; all AUC, 0.99; see Fig E5, B). Therefore we used MAT-AUC as the outcome measure for further analyses.

**Test performance characteristics of MATs compared with existing diagnostics for peanut allergy.** All 42 patients in the validation cohort underwent conventional allergy testing (SPTs and sIgE measurement to peanut), as well as component testing and BATs. We assessed the performance characteristics (sensitivity and specificity) for each test by using DBPCFCs as the reference. The study team was blinded to the results of the diagnostic tests at the time of challenge to prevent bias. By using ROC curve analysis, MATs had the most favorable discrimination performance (AUC, 0.99) compared with the other diagnostic tests (Fig 4, A, and Table II).

We undertook a further analysis in a subgroup of 24 peanut-sensitized patients with equivocal results for conventional allergy tests (see Table E3 in this article’s Online Repository at www.jacionline.org). In this subgroup of patients, MATs continued to trend toward superior discrimination.

**TABLE I.** Demographic and clinical characteristics of patients assessed for peanut allergy

|                         | Patients with peanut allergy (n = 30) | Peanut-sensitized but tolerant subjects (n = 12) | P value |
|-------------------------|--------------------------------------|-----------------------------------------------|--------|
| Age (y)                 | 13.5 (11-17)                         | 17.5 (9-29)                                   | .36    |
| Male sex (%)            | 50                                   | 75                                            |        |
| SPT response to peanut (mm) | 10 (7-12)                           | 7 (5-9)                                       | .02    |
| IgE to peanut (kU/L)    | 26 (5.5-85)                          | 0.35 (0.3-2.0)                                | <.001  |
| IgE to Ara h 1 (kU/L)   | 3.9 (<0.1-27)                        | <0.1 (<0.1-0.23)                              | <.001  |
| IgE to Ara h 2 (kU/L)   | 13.6 (3.1-80)                        | 0.2 (<0.1-0.6)                                | <.001  |
| IgE to Ara h 3 (kU/L)   | 0.45 (<0.1-7.0)                      | <0.1 (<0.1-0.1)                               | <.001  |
| IgE to Ara h 8 (kU/L)   | <0.1 (<0.1-6.0)                      | 0.29 (<0.1-2.9)                               |        |
| Reaction severity at DBPCFC Mueller grade 1: | 6 (20%) | NA |        |
|                         | Mueller Grade 2: 9 (30%)             | NA                                            |        |
|                         | Mueller Grade 3: 15 (50%)            | NA                                            |        |

Data are expressed as medians (interquartile ranges). P value refers to a comparison between patients with peanut allergy and peanut-tolerant subjects using the Mann-Whitney test. Boldface indicates P < .05.

NA, Not available.
reproducibility compared with other diagnostic tests (Fig 4, B, and Table II).

Reproducibility of MATs compared with BATs. MAT responses in the validation cohort were assessed on at least 2 separate occasions in 25 patients with peanut allergy who also underwent BATs. We calculated ICC (ie, reproducibility of MATs on the same sample on different occasions by using different pooled hMCs). We used ICC rather than coefficient of variation because the former is a more appropriate measure of intersay variability where there is no natural zero point. Overall, the ICC for BATs performed on the same patients on 2 separate occasions up to 4 weeks apart was 0.43 (95% CI, 0.27-0.57).

Exploratory analysis to identify patterns of response in MATs. We used data-driven analyses to identify whether there were subgroups of patients with similar MAT responses among the total cohort of 42 peanut-sensitized patients. MAT-AUC, % CD63, and see Fig E10 in this article’s Online Repository at www.jacionline.org). The optimal number of clusters was 2, and see Fig E10 in this article’s Online Repository at www.jacionline.org). When we related the clusters to clinically defined severity of peanut allergy ascertained by DBPCFCs, cluster 1 corresponded to sensitized patients who were either nonreactive or experienced symptoms only at relatively high levels of exposure (>4.4 g peanut protein, approximately 20 peanuts), although the higher clusters corresponded to patients who reacted to far lower levels of exposure with a tendency toward more significant systemic reactions (see Table E4 in this article’s Online Repository at www.jacionline.org).

To compare the discriminatory power of sIgE measurement in comparison with the MAT, we also undertook k-means clustering on sIgE data (see Fig E11 in this article’s Online Repository at www.jacionline.org). The optimal number of clusters was 2, with the clustering distinguishing between patients with low versus those with high sIgE levels. When we compared the 2 partitions by plotting patients on the space defined by variable sIgE levels and the first FPC (relating to MAT the response), the response for MAT clusters 4 and 5 appeared to be independent of sIgE levels (Fig 6).

**DISCUSSION**

We developed a robust and reproducible MC-based assay to improve the diagnosis of IgE-mediated allergy using human MCs derived from human progenitor cells. hMCs sensitized with sera

### TABLE II. Discrimination performance of different diagnostic tests for peanut allergy in the principle study population (n = 42) and a subcohort of participants with equivocal tests (SPT or sIgE measurement, n = 24)

| Population                  | Diagnostic tests          | Optimal cutoff* | AUC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) | PLR (95% CI) | NLR (95% CI) | Odds ratio (95% CI) |
|-----------------------------|---------------------------|----------------|--------------|----------------------|----------------------|--------------|--------------|---------------------|
| Whole population (n = 42)   | SPT (mm)                  | 8              | 0.73 (0.56-0.90) | 70 (50-85)           | 75 (43-95)           | 2.8 (1.0-7.7) | 0.08 (0.08-0.41) | 7 (1.5-32.1)        |
|                             | sIgE to peanut (kU/L)     | 3.8            | 0.93 (0.85-1.0) | 83 (65-94)           | 92 (62-100)          | 10 (1.5-66)  | 0.18 (0.08-0.41) | 55 (5.7-527)        |
|                             | sIgE to Ara h 2 (KUA/L)   | 1.64           | 0.93 (0.86-1.0) | 77 (58-90)           | 83 (52-98)           | 4.6 (1.3-16) | 0.28 (0.14-0.56) | 16.4 (2.9-93)       |
|                             | BAT, % CD63               | 7.8            | 0.94 (0.87-1.0) | 80 (61-92)           | 89 (52-100)          | 7.2 (1.1-46) | 0.22 (0.11-0.48) | 32 (3.3-308)        |
|                             | MAT-AUC                   | 6.3            | 0.99 (0.96-1.0) | 97 (83-100)          | 92 (62-100)          | 11.6 (1.8-76) | 0.04 (0.01-0.25) | 319 (18.3-5556)     |
| Subgroup with equivocal SPT/sIgE results (n = 24) | SPT (mm)                  | 8              | 0.70 (0.48-0.90) | 75 (50-85)           | 75 (43-95)           | 3.0 (1.1-8.4) | 0.33 (0.12-0.94) | 9 (1.4-57)          |
|                             | Specific IgE (KUA/L)      | 0.43           | 0.83 (0.65-1.0) | 100 (74-100)         | 67 (62-100)          | 3.0 (1.4-6.7) | 0           | ∞                   |
|                             | Ara h 2 (KUA/L)           | 0.72           | 0.83 (0.66-0.99) | 75 (43-95)           | 83 (52-98)           | 4.5 (1.2-16) | 0.30 (0.11-0.83) | 15 (2.0-111)        |
|                             | BAT, % CD63               | 10.5           | 0.84 (0.67-1.0) | 83 (52-98)           | 78 (40-97)           | 3.8 (1.1-13) | 0.21 (0.06-0.80) | 17.5 (2.0-156)      |
|                             | MAT-AUC                   | 6.3            | 0.97 (0.90-1.0) | 92 (62-100)          | 92 (62-100)          | 11.0 (1.7-72) | 0.09 (0.01-0.60) | 121 (6.7-2188)      |

NLR, Negative likelihood ratio; PLR, positive likelihood ratio.

*Optimal cutoffs were determined by using the Youden index.
from patients with peanut, grass pollen, and Hymenoptera (wasp venom) allergy demonstrated allergen-specific and dose-dependent degranulation by using both expression of surface activation markers (CD63 and CD107a) and functional assays (PGD2 and β-hexosaminidase release). The MAT is a very sensitive assay, with significant levels of surface expression of CD63 activation markers after stimulation with peanut at concentrations up to 2-log lower than that required for the BAT. We have shown that in the cohort of peanut-sensitized patients who underwent DBPCFCs to peanut, our novel MAT appeared to confer superior diagnostic accuracy compared with existing diagnostics in distinguishing between patients with clinical reactivity and those who did not react to DBPCFCs.

Our data imply that the MAT response is not just dependent on serum specific IgE levels. When we compared the partitions obtained by using k-means clustering on sIgE data with that relating to MAT response, the latter appeared to be independent of sIgE (Fig 6, D). This is consistent with our observation of 2 separate groups of patients when comparing the MAT readout (measured by CD-sens, a marker of MC sensitivity): one group had a higher MAT sensitivity to the same level of sIgE (Fig 3, B). Thus the MAT response does not appear to depend exclusively on the concentration of sIgE levels, suggesting that hMC degranulation can be regulated by additional elements, such as affinity or a combination of allergen IgE specificities that vary between subjects.
In addition to diagnosis, other potential applications of the MAT could include investigations of the intracellular communication pathways and molecular mechanisms engaged in the IgE-mediated activation of these cells to allergen, the assessment of MAT responses to different allergen epitopes, and, given the very high sensitivity of MAT, assessment for the unintended presence of food allergens during food production. The MAT might therefore be useful as an aid to associated risk allergen management.

We found hMC cultures to be stable, reproducible, and highly sensitive (responding to concentrations of peanut <1 μg/mL); these characteristics mean they are ideal tools to investigate the unique effector functions of human MCs. Our protocol used culture media free of serum, thus reducing the risk of nonspecific patient-protein interactions. Some groups have attempted to standardize diagnostic methods by using cell lines (eg, humanized rat basophilic leukemic cells [RBL-2H3 cells] or human leukemic MCs [LAD2 cells]) that express FcεRI, the high-affinity IgE receptor.

A number of groups have sought to assess and validate the BAT for the diagnosis of peanut allergy. There are similarities in methodology between BATs and MATs, with both techniques using flow cytometry to assess the expression of surface activation markers after incubation with allergen in vitro. However, the BAT requires fresh blood, which is ideally processed within 4 hours of collection. Some groups have sought to perform BATs up to 24 hours after sampling, which results in downregulation of surface activation marker expression; to date, the effect of this downregulation on diagnostic accuracy has not been assessed. The requirement to analyze fresh blood samples affects the feasibility of the BAT and has limited its use to a few specialist centers. Moreover, basophils from 6% to 17% of the population do not respond to IgE under standard BAT conditions, and BATs cannot be used for these subjects. In contrast, the MAT uses serum samples, which can be frozen and batch tested in a central facility. Although the differentiation of hMCs from blood progenitors requires time and specific expertise, this could take place in specialist centers, with the possibility of supplying hMCs to external laboratories. Our preliminary data, showing improved diagnostic performance of the MAT compared with other techniques, are convincing arguments to pursue further development of the MAT for clinical testing.

To ensure quality control across batches of hMCs, in each testing run we included an internal control and positive control (anti-IgE). Each batch was generated from 3 to 9 pooled donors, which reduces the risk of specific donor dependence and increases reproducibility. We confirmed this by assessing the MAT response on at least 2 separate occasions and assessing ICC, which was high. In contrast, the ICC for the BAT was much lower, an observation that likely represents the inherent biological variability in basophil reactivity from one day to another. One advantage of the BAT is that it evaluates both effector cell reactivity and serum factors (sIgE and IgG isotypes). However, in the context of food allergy, it is unclear as to the relative contributions to circulating basophils versus tissue-resident MCs. The observation that the MAT has better discrimination performance than the BAT implies that clinical reactivity/tolerance might depend more on serum factors (which are assessed by using the MAT) as opposed to basophil reactivity.

The peanut-sensitized patients used for the initial validation of the MAT are not representative of a general clinic population with indeterminate diagnostics, who might otherwise be selected to...
undergo a formal food challenge to clarify a diagnosis. We attempted to correct for this by including a subanalysis including only patients with indeterminate standard diagnostic tests (SPT response < 8 mm, sIgE level < 15 kU/L). The results in this group of patients indicated that the MAT can confer improved diagnostic accuracy over existing allergy tests. However, further evaluation in a more representative clinic cohort is needed to confirm these findings.

Our exploratory data-driven analysis of MAT responses in patients with peanut allergy suggested that the patterns of response in the MAT can provide information relating to clinical reactivity, identifying the patients most at risk of significant anaphylaxis. If proved correct, this would be clinically very useful because no other diagnostic tests can predict the severity of the reaction on exposure. However, in this context our study generated a hypothesis that will require further studies to verify it.

In conclusion, we developed an MC-based assay to improve the diagnosis of IgE-mediated allergy that was robust and reproducible. Compared with other commonly used diagnostic tests, our novel MAT appeared to confer superior diagnostic accuracy in distinguishing between patients with true peanut allergy and those who are sensitized but tolerant to peanut.

We thank Dr Gareth Howell at the Flow Cytometry facility, Manchester Collaborative Centre for Inflammation Research (MCCIR), University of Manchester, for his assistance. We thank Dr Mihaela Zidarn, Dr Renato Erzen, and Dr Julij Selb (Slovenia) and Professor Stephen Durham, Dr Robert Boyle, and Dr Isabel Skyplala for their clinical support. We also thank all the volunteers who provided samples for the analyses presented in this report. Some of the adult participants in this study were initially recruited for the TRACE Peanut study (funded by the UK Food Standards Agency), and we are grateful to the study investigators (CI A. Clark) and the Food Standards Agency for their support.

Key messages
- We developed a robust and reproducible novel MC-based assay (by using primary human MCs generated from peripheral blood precursors).
- Compared with existing diagnostic tests, our novel MAT appeared to confer superior diagnostic accuracy in distinguishing between peanut-sensitized patients with and without clinical reactivity.

REFERENCES
1. Nwaru BI, Hickstein L, Panesar SS, Roberts G, Muraro A, Sheikh A, et al. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy 2014;69:992-1007.
2. Turner PJ, Gowland MH, Sharma V, Ierodiakonou D, Harper N, Garcez T, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol 2015;135:596-63.
3. Turner PJ, Boyle RJ. Food allergy in children: what is new? Curr Opin Clin Nutr Metab Care 2014;17:285-93.
4. Sampson HA, Gerth-von Sallmann H, Ierodiakonou D. Are there different phenotypes of food allergy? J Allergy Clin Immunol 2017;140:750-8.e15.
5. Statement by the American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma & Immunology and the Canadian Society of Allergy and Clinical Immunology relating to fatality during food challenge test. Available at: http://csaci.ca/wp-content/uploads/2017/08/Statement-to-public-regarding-OFCl-fatality-FINAL.pdf. Accessed August 31, 2017.
6. Sicherer SH, Allen K, Lack G, Taylor SL, Donovan SM, Oria M. Critical issues in food allergy: a National Academies consensus report. Pediatrics 2017 [Epub ahead of print].
7. Osborne NJ, Koplin JJ, Martin PE, Gurin LC, Lowe AJ, Matheson MC, et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol 2011;127:668-76.
8. Nicolaou N, Poorashraf M, Murray C, Simpson A, Winnell H, Kerry G, et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol 2010;125:191-7.
9. Custovic A, Nicolaou N. Peanut allergy: overestimated in epidemiology or under-diagnosed in primary care? J Allergy Clin Immunol 2011;127:631-2.
10. Patelis A, Borres MP, Kober A, Berthold M. Multiplex component-based allergen microarray in recent clinical studies. Clin Exp Allergy 2016;46:1022-32.
11. Santos AF, Shreffler WG. Road map for the clinical application of the basophil activation test in food allergy. Clin Exp Allergy 2017;47:1115-24.
12. Souares-Weiser K, Takwoingi Y, Panesar SS, Muraro A, Werfel T, Hoffmann-Sommergruber K, et al. The diagnosis of food allergy: a systematic review and meta-analysis. Allergy 2014;69:76-86.
13. Mastrofi L, Mattson L, Zuidmeer-Jongejan L, Lidholm J, Andersson K, Akkerdaas JH, et al. Sensitization to Cor a 9 and Cor a 14 is highly specific for a hazelnut allergy with objective symptoms in Dutch children and adults. J Allergy Clin Immunol 2013;132:393-9.
14. MacGlashan DW Jr. Basophil activation testing. J Allergy Clin Immunol 2013;132:777-87.
15. Santos AF, Douiri A, Bécares B, Wu SY, Stephens A, Radulovic S, et al. Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children. J Allergy Clin Immunol 2014;134:64-52.
16. Santos AF, Lack G. Basophil activation test: food challenge in a test tube or specialist research tool? Clin Transl Allergy 2016;6:10.
17. Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy 2015;70:1393-405.
18. Reber LL, Hernandez JD, Gali SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol 2017;140:335-48.
19. Dreyer DF, Barrett NA, Austen KF. Immunological Genome Project Consortium. Expression profiling of constitutive mast cells reveals a unique identity within the immune system. Nat Immunol 2016;17:878-87.
20. Huang H, Li Y, Liu B. Transcriptional regulation of mast cell and basophil lineage commitment. Semin Immunopathol 2016;38:539-48.
21. Schmetzer O, Valentin P, Smorodchenko A, Domenis R, Gri S, Siebenhaar F, et al. A novel method to generate and culture human mast cells: peripheral CD34+ stem cell-derived mast cells (PSCMCs). J Immunol Methods 2014;413:62-8.
22. Saito H, Kato A, Matsumoto K, Okayama Y. Culture of human mast cells from peripheral blood. J Immunol Methods 2016;413:62-8.
23. Jordan R, Gaudenzio N, Rodrigues M, Lopez J, Blanchard N, Valutti S, et al. Mast cells form antibody-dependent degranulatory synapse for dedicated secretion and defence. Nat Commun 2015;6:6174.
24. Koroec P, Turner PJ, Silar M, Kopac P, Kosnik M, Gibbs BB, et al. Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis. J Allergy Clin Immunol 2017;140:750-8.e15.
25. Johanson SG, Nopp A, van Hage M, Olofsson N, Lundahl J, Wåhlin L, et al. Passive IgE-sensitization by blood transfusion. Allergy 2005;60:1192-9.
26. Koroec P, Ziberna K, Silar M, Deizman M, Celesnik Smodiš N, Rijavec M, et al. Immunological and clinical factors associated with adverse systemic reactions during the build-up phase of honeybee venom immunotherapy. Clin Exp Allergy 2015;45:1579-89.
27. Eisenberg DT. Telomere length measurement validity: the coefficient of variation is not a single value but a range. Nat Immunol 2016;17:878-87.
28. Silverman BW, Ramsay JO. Functional Data Analysis. 2nd ed. New York: Springer; 2005.
29. Charrad M, Ghazzali N, Boiteau V, Niknafs A. Nbclust: an R package for determining the relevant number of clusters in a data set. J Stat Softw 2014;61:1-36.
30. Metcalfe DD, Pawankar R, Ackerman SJ, Akin C, Clayton F, Falcone FH, et al. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J 2016;9:7.
31. Roberts G, Ollert M, Alberse R, Austin M, Custovic A, DunnGalvin A, et al. A new framework for the interpretation of IgE sensitization tests. Allergy 2016;71:1540-51.
32. Genolini C, Falissard B. KmL: a package to cluster longitudinal data. Comput Methods Programs Biomed 2011;104:112-21.
33. Blanc F, Adel-Patient K, Drumare MF, Paty E, Wal JM, Bernard H. Capacity of purified peanut allergens to induce degranulation in a functional in vitro assay: Ara h 2 and Ara h 6 are the most efficient elicitors. Clin Exp Allergy 2009;39:1277-85.
34. Ladics GS, van Bilsen JH, Brouwer HM, Vogel L, Vieths S, Knippels LM. Assessment of three human FcepsilonRI-transfected RBL cell-lines for identifying IgE induced degranulation utilizing peanut-allergic patient sera and peanut protein extract. Regul Toxicol Pharmacol 2008;51:288-94.
35. Santos AF, James LK, Bahnson HT, Shamji MH, Couto-Francisco NC, Islam S, et al. IgF24 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol 2015;135:1249-56.
36. Kirshenbaum AS, Petrik A, Walsh R, Kirby TL, Vepa S, Wangsa D, et al. A ten-year retrospective analysis of the distribution, use and phenotypic characteristics of the LAD2 human mast cell line. Int Arch Allergy Immunol 2014;164:265-70.
37. Passante E. Mast cell and basophil cell lines: a compendium. Methods Mol Biol 2014;1192:101-13.
38. Thomas K, Herouet-Guichene C, Ladics G, McClain S, MacIntosh S, Privalle L, et al. Current and future methods for evaluating the allergenic potential of proteins: international workshop report 23-25 October 2007. Food Chem Toxicol 2008;46:3219-25.
39. Gentinetta T, Pecaric-Petkovic T, Wan D, Falcone FH, Dahinden CA, Pichler WJ, et al. Individual IL-3 priming is crucial for consistent in vitro activation of donor basophils in patients with chronic urticaria. J Allergy Clin Immunol 2011;128:1227-34.
40. Mukai K, Gaudenzio N, Gupta S, Vivanco N, Bendall SC, Maeccker HT, et al. Assessing basophil activation by using flow cytometry and mass cytometry in blood stored 24 hours before analysis. J Allergy Clin Immunol 2017;139:889-99.e11.
41. Nicolaou N, Custovic A. Molecular diagnosis of peanut and legume allergy. Curr Opin Allergy Clin Immunol 2011;11:222-8.
METHODS

Development of the MAT

Immunocytochemistry. hMCs were fixed in 4% paraformaldehyde in PBS for 10 minutes, allowed to settle on glass slides (Superfrost+; CellPath, Powys, United Kingdom), washed in PBS, and air-dried for a minimum of 1 hour. Cells were blocked in 10% normal goat serum (Vector Laboratories, Burlingame, Calif) diluted in PBS containing 0.1% Tween 20 (PBST) at room temperature for 30 minutes, followed by incubation with a mixture of anti-tryptase (ab2378; Abcam, Cambridge, United Kingdom; diluted 1:2000) and anti-chymase (ab186417; Abcam; diluted 1:2000) antibodies diluted in the blocking solution for 1 hour in a humid chamber at room temperature. Slides were washed in 3 changes of PBST over 9 minutes and incubated in a mixture of Alexa Fluor 488 anti-rabbit (ab150081; Abcam; diluted 1:200) and Alexa Fluor 555 anti-mouse (A-21424; Thermo Fisher Scientific; diluted 1:200) antibodies for 30 minutes in a humid chamber at room temperature. Slides were washed in PBST as above and mounted with glass coverslips by using Fluoroshield mountant containing 4'-6-diamidino-2-phenylindole dihydrochloride (ab104139; Abcam). Images were collected on a Olympus BX51 upright microscope (Olympus, Center Valley, Pa) by using a 20×0.50 UPlanFlN objective and captured using a CoolSNAP EZ camera (Photometrics, Tucson, Ariz) linked to MetaVue Software (Molecular Devices, Sunnyvale, Calif). Specific band pass filter sets for 4′-6-diamidino-2-phenylindole dihydrochloride, fluorescein isothiocyanate, and Texas red were used to prevent bleed through from one channel to the next. Images were then processed and analyzed with ImageJ software (http://rsb.info.nih.gov/ij; National Institutes of Health, Bethesda, Md).

Allergen source

Peanut extract for MATs. Commercially available, lightly roasted, mechanically defatted peanut flour was obtained from Golden Peanut Company (Alpharetta, Ga). Samples were ground with a pestle and mortar and defatted by means of 2-stage addition of hexane (1:10 wt/vol) for 3 hours and then overnight. Protein was extracted with 50 mmol/L Tris-HCl, pH 8.8 (1:50 wt/vol), for 1 hour with mixing at ambient temperature. Extracts were clarified by means of centrifugation (15,000g for 10 minutes), and protein was quantified by using the 2D-Quant assay kit (GE Healthcare, Buckinghamshire, United Kingdom). Confirmation of IgE binding to the extract was undertaken by using 1-dimensional PAGE and IgE immunoblotting.

Recombinant peanut allergens. The recombinant peanut allergens rAra h 1 (accession no. P43238), rAra h 3 (O82580), rAra h 2 (Q6PSU2), rAra h 6 (Q647C9), and rAra h 8 (BOYU5) used in this study are recombinant proteins produced in Escherichia coli and were provided by EUROIMMUN AG. Timothy grass pollen allergen extract was kindly provided as well by EUROIMMUN AG. The peanut components had been tested according to quality process/criteria, including multiple steps, such as SDS-PAGE, Western blotting, mass spectrometry, and a serologic test with reference sera.

Wasp venom. Wasp venom was sourced from Hal Allergy (Leiden, The Netherlands).

Validation, diagnostic performance, and comparison of MATs with other diagnostic tests

SPTs. SPTs were performed to commercially available extracts (ALK-Abelló, Hørsholm, Denmark) by using single-point lancets, according to national guidelines. Histamine (10 mg/mL; Stallergenes) was used as a positive control. A positive SPT response was defined as a wheal size of at least 3 mm larger than that elicited by a saline control read at 15 minutes.

DBPCFCs to peanut. DBPCFCs were conducted according to international consensus criteria (PRACTALL). In brief, subjects underwent double DBPCFCs over 2 separate days at least 14 days apart. On each day, subjects received increasing doses every 30 minutes of peanut protein (or placebo) at 3, 10, 30, 100, 300, 1000, and 3000 mg until stopping criteria were met (as per PRACTALL consensus). The order of DBPCFC challenges was determined by using a computer-generated randomization table (http://www.randomization.com). All members of the research team were blinded to the challenge assignment aside from the technician preparing the challenge material.

Measurement of IgE and IgG antibody levels. Levels of total IgE, peanut-specific IgE, and IgE to the allergen components rAra h 1, 3, 2, 6, 8, and 9 were measured by using ImmunoCAP (Thermo Fisher Scientific). IgG levels to peanut were measured with the Phadia 250 Laboratory System.

FDA: Statistical learning and explanatory notes

Derivatives of response curves. In FDA the first and second derivatives provide useful insight into the dynamic of the investigated phenomenon. Fig E6 demonstrates the presence of distinct groups of responses with different velocity and acceleration. To further interpret these findings, we used the methodology of Silverman and Ramsay to plot the overall mean function and the functions obtained by adding and subtracting a suitable multiple of the principal component function in question.

To better investigate the structure underlying the data, we plotted the principal component scores for pairs of harmonics to ascertain how the curves are distributed within the K-dimensional subspace spanned by the eigen functions (Fig E7).

Optimal number of clusters. The choice of the optimal number of clusters has been based on 30 different evaluation indices. According to the majority rule, we have selected a 5-cluster solution (Fig E8).

Functional t test. Functional t tests revealed that the clusters were significantly different from one another. There was little evidence of differences for clusters 1 and 2, 1 and 3, and 2 and 3 for low allergen concentrations. However, evidence of significant differences is found for higher doses (Fig E9). This is not surprising because the response curves in these clusters overlap for low doses, and the separation becomes evident after exposure to higher concentrations. On the contrary, clusters 4 and 5 differed only for low to moderate concentrations, whereas little evidence was found for higher doses.

Derivatives of the response curves in clusters.

Applying partitions to the derivatives revealed interesting characteristics of the clusters (Fig E10). Velocity in cluster 5 was high for low allergen concentrations and then decreased for high doses. This implies that patients in this cluster exhibit a high response also for low doses. Cluster 1 showed a constant velocity at 0, implying no response, whereas the other clusters present low velocity for low doses that quickly increase until their highest response is reached. The moderate responses presented high variability in terms of velocity and acceleration.

K-means clustering on specific IgE data. To compare the discriminatory power of IgE in comparison with the MAT assay, we also ran k-means clustering on specific IgE data (Fig E11). The optimal number of clusters was 2, with the clustering distinguishing between patients with low versus those with high IgE levels.

REFERENCES

E1. Sangmoen HA, Gerth van Wijk R, Bindlev-Jensen C, Sicherer S, Teuber SS, Burks AW, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol 2012;130:1260-74.

E2. Silverman BW, Ramsay JO. Functional Data Analysis. 2nd ed. New York: Springer; 2005.

E3. Charrad M, Ghazzáli N, Boiteau V, Niknafs A. NbClust: an R package for determining the relevant number of clusters in a data set. J Stat Softw 2014;61:1-36.
FIG E1. Characterization of hMCs. **A,** After 8 to 10 weeks of culture, hMC maturation was controlled by measuring the size granularity, (side scatter [SSC]-H/forward scatter [FSC]-H) and CD117 surface expression by using flow cytometry. Control shows fluorescence minus one values for CD117 control staining. **B,** Serum IgE binding. hMCs were sensitized overnight with human serum (1:10 dilution) or not for control hMCs and washed. IgE fixed on the surfaces of hMCs was detected by using flow cytometry. Numbers represent percentage cells in the gate. **C** and **D,** Immunofluorescence for tryptase (Fig E1, C) and chymase (Fig E1, D). A spectrum of tryptase and chymase expression is seen within the MC population. **E** and **F,** MC metachromatic granules were identified by using May-Grünwald Giemsa (Fig E1, E) or toluidine blue (Fig E1, F) staining.
FIG E2. Correlation of surface expression and mediators release measurement. hMCs were sensitized overnight with serum from patients with peanut allergy, patients with grass pollen allergy, or both (volume ratio, 1:10); washed; and either left untreated or exposed for 1 hour to different concentrations of peanut or grass pollen extract or anti-IgE (10 μg/mL) as a positive control. hMC degranulation was measured by CD63 and CD107a surface staining and analyzed by using flow cytometry. β-Hexosaminidase levels were measured in cell pellets, as well as in supernatants, and expressed as percentage β-hexosaminidase release. PGD2 levels were measured in supernatants. The assay was performed in duplicates or triplicates with pooled hMCs from at least 3 different healthy donors. Correlations were calculated by using Spearman R (R^2) values (A) with both absolute values and percentages of readout induced by anti-IgE summarized in B.
hMCs are more susceptible to IgE-mediated degranulation than LAD2 cells. hMCs were sensitized overnight with 1 μg/mL human IgE washed and either left untreated (0 μg/mL) or exposed for 1 hour to anti-IgE (10 μg/mL).

A and B, hMC degranulation was measured based on CD63 (Fig E3, A) and CD107a (Fig E3, B) surface staining and analyzed by using flow cytometry.

C, β-Hexosaminidase levels were measured in cell pellets, as well as in supernatants. Percentage of β-hexosaminidase release is shown.

D, PGD2 levels were measured in supernatants. The assay was performed with pooled hMCs from at least 3 different healthy donors.
hMC degranulation in patients with a clinical history of systemic reaction to wasp (n = 21) or honeybee (n = 6) venom. hMCs were sensitized overnight with patients’ sera, washed, and then incubated with varying concentrations of wasp venom extract (as indicated) for 1 hour. hMC degranulation was measured based on CD63 surface expression by using flow cytometry.
A

Crude peanut extract (ng/ml)

% CD63+ hMCs

0.01 0.1 1 10 100

B

Corresponding ROC curve. AUC, Area under curve; PN, peanut.

FIG E5. hMC degranulation in peanut-sensitized patients from the validation cohort (n = 42). A, hMCs were sensitized overnight with patients’ sera, washed, and then incubated with varying concentrations of peanut extract (as indicated) or anti-IgE (10 μg/mL) for 1 hour. hMC degranulation was measured based on CD63 surface expression by using flow cytometry. B, Corresponding ROC curve. AUC, Area under curve; PN, peanut.
FIG E6. First and second derivatives of response curves for peanut-sensitized patients.
FIG E7. Scores of patients on the first 2 principal components of the allergic response.
FIG E8. Evaluation measures distribution for the choice of the optimal number of cluster obtained with the package NbClust.
FIG E9. Functional t test for differences between responses in the 5 clusters.
FIG E10. Velocity and acceleration in the distinct response patterns in the clusters.
FIG E11. K-means clustering on sIgE data in patients with peanut allergy. A, MAT responses on the first 2 principle components, assigned to the 2 IgE clusters detected. B, IgE clusters on MAT response curves to peanut.
TABLE E1. Serum IgE and IgG levels and associated clinical symptoms of the 14 patients with peanut allergy whose sera were used in the development of MATs

| Patient no. | Total IgE (kU/L) | Timothy grass | Peanut | Ara h 1 | Ara h 2 | Ara h 3 | Ara h 6 | Ara h 8 | Ara h 9 | Specific IgE (kU/L) to: | slgG to peanut (kU/L) | Symptoms reported during accidental exposure |
|------------|------------------|----------------|--------|--------|--------|--------|--------|--------|--------|------------------|------------------|------------------------------------------------|
| A          | 1300             | ND             | 437    | 116    | 180    | 59.8   | 27.06  | 6.79   | 3.76   | 6.87             | 6.87             | Vomiting, urticaria, loss of consciousness |
| B          | 460              | 20.6           | 95.1   | 40.2   | 49.5   | 14.7   | 18.03  | 0.4    | <0.35  | 7.69             | <0.35  | Lip angioedema, vomit × 2, throat tightness with vocal hoarseness, cough, dizziness |
| C          | 1400             | ND             | 240    | 65.3   | 96.3   | 2.07   | 40.59  | <0.35  | <0.35  | 8.88             | <0.35  | Generalized pruritus, mild angioedema, nausea, diarrhea, dyspnea with wheeze, dizziness |
| D          | 1500             | >100           | 257    | 65.3   | 136    | 19.6   | 22.65  | 62.6   | <0.35  | 10.3             | <0.35  | Swollen mouth, tight throat, difficulty breathing, abdominal pain |
| E          | 1400             | 50.7           | 9.6    | <0.35  | 4.6    | <0.35  | 3.44   | 15.5   | <0.35  | 2.75             | <0.35  | Vomiting and abdominal cramps, chest tightness, and wheeze |
| F          | 55.4             | <0.35          | 7.3    | 2.6    | <0.35  | 3.7    | <0.35  | 5.96   | <0.35  | <2               | <0.35  | Facial angioedema and dyspnea |
| G          | 48.6             | ND             | 15.3   | 1.5    | 8      | 0.8    | 4.06   | <0.35  | <0.35  | 3.72             | <0.35  | Lip angioedema, throat tightness, nausea, and vomiting |
| H          | 190              | 19.5           | 66.7   | 29.6   | 25.2   | 21.4   | 6.78   | <0.35  | <0.35  | 8.18             | <0.35  | Oral pruritus, dyspnea, pruritic rash over trunk |
| I          | 370              | 12.9           | 22.1   | 8      | 11.5   | 0.5    | 6.36   | 2.5    | <0.35  | 4.3              | <0.35  | Nausea, vomiting, dyspnea with chest tightness, loss of consciousness |
| J          | 430              | 1.5            | 4.3    | 0.4    | 6.2    | <0.35  | 4.45   | <0.35  | <0.35  | 4.04             | <0.35  | Nausea, chest pain, dysphagia and dyspnea, flushing |
| K          | 480              | 4.3            | 4.6    | <0.35  | 1      | <0.35  | 0.49   | <0.35  | 21     | 4.27             | <0.35  | Throat tightness, hoarse voice, dysphagia, nausea, and vomiting |
| L          | 81.6             | 11.3           | 6.6    | 1.81   | 2.09   | <0.35  | 1.42   | 0.45   | <0.35  | 6.06             | <0.35  | Generalized urticaria with facial angioedema, abdominal cramps, chest tightness, and dizziness |
| M          | 140              | ND             | 10.6   | 8      | 2.5    | <0.35  | 2.58   | <0.35  | <0.35  | <2               | <0.35  | Dysphagia, dyspnea with wheeze, facial angioedema, generalized rash, abdominal cramps |
| N          | 1600             | ND             | 5.5    | 6.97   | <0.35  | <0.35  | <0.35  | 6.48   | <0.35  | 3.07             | <0.35  | Generalized urticaria, facial flushing, throat tightness, and wheezing |

ND, Not determined.
**TABLE E2. Patient demographics: Patients with venom allergy**

|                           | Wasp venom (n = 21) | Honeybee venom (n = 6) |
|---------------------------|----------------------|------------------------|
| Age (y)                   | 41 (29-58)           | 46 (28-56)             |
| Male (%)                  | 66                   | 100                    |
| IgE to wasp venom (kU/L)  | 6.9 (3.1-22.8)       | 0.37 (0.35-0.89)       |
| IgE to bee venom (kU/L)   | <0.35 (<0.35-1.8)    | 2.0 (1.4-6.1)          |
| IgE to rVes v 5 (kU/L)    | 21.7 (6.1-39.5)      | <0.1 (<0.1-2.8)        |
| IgE to rApi m 1 (kU/L)    | <0.1 (<0.1-0.35)     | 0.86 (0.40-2.5)        |
| Reaction severity         | Mueller grade 1: 8 (28%) | Mueller grade 1: 0 |
| causing presentation      | Mueller grade 2: 5 (17%)  | Mueller grade 2: 2 (33%) |
|                           | Mueller grade 3: 5 (17%)  | Mueller grade 3: 2 (33%) |
|                           | Mueller grade 4: 11 (38%) | Mueller grade 4: 2 (33%) |

Data are expressed as medians (interquartile ranges).
TABLE E3. Patient demographics: Subpopulation with equivocal testing defined as either IgE sensitization to peanut equivalent to less than 95% positive predictive values for peanut allergy (IgE <15 kU/L, SPT response < 8 mm)

|                  | Patients with peanut allergy (n = 12) | Peanut-tolerant subjects (n = 12) | P value |
|------------------|---------------------------------------|-----------------------------------|---------|
| Age (y)          | 13.5 (11-19)                          | 17.5 (9-29)                       | .45     |
| Male (%)         | 66                                    | 75                                |         |
| SPT response to peanut (mm) | 10 (7-12)                             | 7 (5-9)                           | .10     |
| IgE to peanut (kU/L) | 4.6 (1.7-7.4)                         | 0.35 (0.3-2.0)                   | .005    |
| IgE to Ara h 1 (kU/L) | <0.1 (<0.1-0.22)                     | <0.1 (<0.1-0.23)                 | .49     |
| IgE to Ara h 2 (kU/L) | 1.3 (0.4-3.9)                        | 0.2 (<0.1-0.6)                   | .006    |
| IgE to Ara h 3 (kU/L) | <0.1 (<0.1-0.17)                    | <0.1 (<0.1-0.1)                  | .37     |
| IgE to Ara h 8 (kU/L) | <0.1 (<0.1-0.7)                    | 0.29 (<0.1-2.9)                  | .62     |
| Reaction severity at challenge | Mueller grade 1: 4 (33%) | Mueller grade 2: 3 (25%) | NA |
|                  |                                       | Mueller grade 3: 5 (42%)         |         |

Data are expressed as medians (interquartile ranges). P value refers to a comparison between patients with peanut allergy and peanut-tolerant subjects by using the Mann-Whitney test. Boldface indicates P < .05.
NA, Not available.
TABLE E4. Clinical characteristics of peanut-sensitized patients by clusters determined by using k-means clustering

|                | Cluster 1       | Cluster 2       | Cluster 3       | Cluster 4       | Cluster 5       |
|----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| No.            | 16              | 6               | 8               | 6               | 6               |
| Age (y)        | 13.8 (11.4-22.8) | 13.3 (12.0-14.8) | 12.0 (9.0-17.7) | 16.3 (13.4-24.8) | 12.1 (11-13.8)  |
| Male sex (%)   | 69              | 66              | 88              | 17              | 17              |
| SPT response to peanut (mm) | 7 (6-8) | 10 (6-13) | 8 (7-11) | 13 (10-20) | 11 (6-12) |
| IgE to peanut (kU/L) | 0.62 (0.32-2.4) | 4.6 (2.6-7.5) | 26.2 (12.8-34) | 72.1 (42.6-95.7) | >100 (85 to >100) |
| IgE to Ara h 2 (kU/L) | 0.29 (0.21-0.87) | 2.6 (0.9-3.8) | 13.0 (8.8-19.3) | 67.1 (26.5-95.3) | >100 (84 to >100) |
| Reaction severity at DBPCFC |                |                |                |                |                |
| No reaction    | 75%             | 0%              | 0%              | 0%              | 0%              |
| Mueller grade 1 | 6%             | 50%             | 0%              | 0%              | 33%             |
| Mueller grade 2 | 0%             | 17%             | 63%             | 33%             | 17%             |
| Mueller grade 3 | 19%            | 33%             | 37%             | 67%             | 50%             |
| Eliciting dose at DBPCFC (peanut protein [g]) | 4.3 (4.3-8.4) | 0.94 (0.44-1.9) | 0.14 (0.043-0.29) | 0.14 (0.066-0.14) | 0.043 (0.043-0.12) |

Data are expressed as medians (interquartile ranges).